Literature DB >> 7233193

Peripherally administered reduced pterins do enter the brain.

G Kapatos, S Kaufman.   

Abstract

The content of tetrahydrobiopterin in rat brain was doubled by peripherally administered tetrahydrobiopterin, with the natural 1 diastereoisomer more effective than the unnatural d configuration. The model pteridine, 6-methyltetrahydropterin was ten times more efficient than tetrahydrobiopterin in crossing the blood-brain barrier, and striatal concentrations of 6-methyltetrahydropterin remained elevated for 2 hours, declining with a half-life of 3 hours. While no evidence for a specific uptake mechanism for concentrating 6-methyltetrahydropterin in cells containing tetrahydrobiopterin was detected, the pterin was found in ts presumed site of action, the nerve terminal. Replacement therapy with reduced pterins may therefore be effective in the treatment of the neurological disorders associated with the variant forms of hyperphenylalaninemia that result from defects in the biosynthesis or metabolism of tetrahydrobiopterin within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7233193     DOI: 10.1126/science.7233193

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  13 in total

Review 1.  Tetrahydrobiopterin as a novel therapeutic intervention for autism.

Authors:  Richard E Frye; Lynne C Huffman; Glen R Elliott
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

2.  Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts.

Authors:  C Bencsics; S R Wachtel; S Milstien; K Hatakeyama; J B Becker; U J Kang
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

3.  A simple and sensitive method for the determination of pterins in cerebrospinal fluid. Clinical usefulness for management of tetrahydrobiopterin deficiency.

Authors:  K Suzuki; M Owada
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

4.  Dihydropteridine reductase deficiency and treatment with tetrahydrobiopterin: a case report.

Authors:  Curtis R Coughlin; Keith Hyland; Rebecca Randall; Can Ficicioglu
Journal:  JIMD Rep       Date:  2012-12-29

5.  Cytosolic and mitochondrial isoenzymes of branched-chain amino acid aminotransferase during development of the rat.

Authors:  H Kadowaki; W E Knox
Journal:  Biochem J       Date:  1982-03-15       Impact factor: 3.857

6.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

7.  Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin.

Authors:  R R McInnes; S Kaufman; J J Warsh; G R Van Loon; S Milstien; G Kapatos; S Soldin; P Walsh; D MacGregor; W B Hanley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

8.  Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man.

Authors:  A Niederwieser; H C Curtius; M Wang; D Leupold
Journal:  Eur J Pediatr       Date:  1982-03       Impact factor: 3.183

9.  The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria.

Authors:  Cary O Harding; Mark Neff; Krzysztof Wild; Kelly Jones; Lina Elzaouk; Beat Thöny; Sheldon Milstien
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

10.  Differences in the metabolism of the aromatic amino acid hydroxylase cofactor, tetrahydrobiopterin, in mutant mice with neurological and immunological defects.

Authors:  D S Duch; S W Bowers; J H Woolf; M T Davisson; L J Maltais; C A Nichol
Journal:  Biochem Genet       Date:  1986-10       Impact factor: 1.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.